Related Experiment Video
Updated: Dec 29, 2025

Using Continuous Data Tracking Technology to Study Exercise Adherence in Pulmonary Rehabilitation
Published on: November 8, 2013
How the EMERGE guideline on medication adherence can improve the quality of clinical trials
Lina Eliasson1, Sarah Clifford1, Amy Mulick2
1Sprout Behaviour Change Ltd, London, UK.
Abstract:
Medication adherence in drug trials is suboptimal, affecting the quality of these studies and adding significant costs. Nonadherence in this setting can lead to null findings, unduly large sample sizes and the need for dose modification after a drug has been approved. Despite these drawbacks, adherence behaviours are not consistently measured, analysed or reported appropriately in trial settings. The ESPACOMP Medication Adherence Reporting Guideline (EMERGE) offers a solution by facilitating a sound protocol design that takes this crucial factor into account. This article summarises key evidence on traditional and newer measurements of adherence, discusses implementation in clinical trial settings and makes recommendations about the analysis and interpretation of adherence data. Given the potential benefits of this approach, the authors call on regulators and the pharmaceutical industry to endorse the EMERGE guideline.
More Related Videos
Related Concept Videos
Drug Therapy
Antianxiety Medications
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioavailability Study Design: Healthy Subjects Versus Patients
Therapeutic Drug Monitoring: Affecting Factors
Dosage Regimens: Designs and Approaches

